Comparative Pharmacology
Head-to-head clinical analysis: GALLIUM GA 68 EDOTREOTIDE versus IOFLUPANE I 123.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GALLIUM GA 68 EDOTREOTIDE versus IOFLUPANE I 123.
GALLIUM GA 68 EDOTREOTIDE vs IOFLUPANE I-123
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gallium Ga 68 edotreotide is a radiopharmaceutical analog of somatostatin that binds to somatostatin receptors, particularly subtype 2 (SSTR2), which are overexpressed on neuroendocrine tumor cells. After binding, internalization occurs, and the gallium-68 isotope emits positrons for PET imaging.
Ioflupane I-123 is a radiopharmaceutical that binds with high affinity to the dopamine transporter (DAT) in the striatum. It allows visualization of presynaptic dopaminergic neurons via single-photon emission computed tomography (SPECT) imaging.
148-259 MBq (4-7 mCi) IV once for PET imaging.
Intravenous: 148-185 MBq (4-5 mCi) administered as a single IV bolus injection over 20-30 seconds, followed by saline flush.
None Documented
None Documented
Clinical Note
moderateIoflupane I-123 + Methylphenidate
"Ioflupane I-123 may decrease effectiveness of Methylphenidate as a diagnostic agent."
Clinical Note
moderateIoflupane I-123 + Venlafaxine
"Ioflupane I-123 may decrease effectiveness of Venlafaxine as a diagnostic agent."
Clinical Note
moderateIoflupane I-123 + Nefazodone
"Ioflupane I-123 may decrease effectiveness of Nefazodone as a diagnostic agent."
Clinical Note
moderateIoflupane I-123 + Fluvoxamine
Terminal elimination half-life: 0.5–2.5 hours (mean 1.2 hours); clinically allows same-day imaging after injection.
Terminal elimination half-life of ioflupane I-123 is approximately 25-30 hours. This prolonged half-life allows for imaging up to 6-8 hours post-injection with sustained target-to-background ratio, but requires consideration for radiation safety.
Renal: >90% unchanged in urine within 24 hours; biliary/fecal: <2%.
Primarily renal; about 60% of administered radioactivity excreted in urine within 24 hours, with 38% as unchanged ioflupane and 22% as metabolites. Fecal excretion accounts for approximately 14% over 48 hours. Additional elimination via biliary route is minimal.
Category C
Category C
Radiopharmaceutical
Radiopharmaceutical
"Ioflupane I-123 may decrease effectiveness of Fluvoxamine as a diagnostic agent."